Monalizumab: inhibiting the novel immune checkpoint NKG2A

The implementation of immune checkpoint inhibitors to the oncology clinic signified a new era in cancer treatment. After the first indication of melanoma, an increasing list of additional cancer types are now treated with immune system targeting antibodies to PD-1, PD-L1 and CTLA-4, alleviating inhi...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Immunother Cancer
Asıl Yazarlar: van Hall, Thorbald, André, Pascale, Horowitz, Amir, Ruan, Dan Fu, Borst, Linda, Zerbib, Robert, Narni-Mancinelli, Emilie, van der Burg, Sjoerd H., Vivier, Eric
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2019
Konular:
Review
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6798508/
https://ncbi.nlm.nih.gov/pubmed/31623687
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0761-3
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller